NASDAQ:OTLK Outlook Therapeutics (OTLK) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free OTLK Stock Alerts $7.63 -0.32 (-4.03%) (As of 01:45 PM ET) Add Compare Share Share Today's Range$7.62▼$8.0450-Day Range$5.73▼$11.9452-Week Range$4.00▼$40.60Volume104,130 shsAverage Volume477,591 shsMarket Capitalization$99.27 millionP/E RatioN/ADividend YieldN/APrice Target$46.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Outlook Therapeutics alerts: Email Address Outlook Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside508.5% Upside$46.43 Price TargetShort InterestBearish7.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 11 Articles This WeekInsider TradingAcquiring Shares$22,245 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.99) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.73 out of 5 starsMedical Sector660th out of 921 stocksBiological Products, Except Diagnostic Industry101st out of 152 stocks 3.4 Analyst's Opinion Consensus RatingOutlook Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOutlook Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Outlook Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.65% of the float of Outlook Therapeutics has been sold short.Short Interest Ratio / Days to CoverOutlook Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Outlook Therapeutics has recently increased by 11.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOutlook Therapeutics does not currently pay a dividend.Dividend GrowthOutlook Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OTLK. Previous Next 1.7 News and Social Media Coverage News SentimentOutlook Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Outlook Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 18 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -68% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Outlook Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $22,245.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Outlook Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.20% of the stock of Outlook Therapeutics is held by institutions.Read more about Outlook Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Outlook Therapeutics are expected to grow in the coming year, from ($2.99) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Outlook Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Outlook Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Outlook Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama’s Forever Term [exposed]Over a decade ago, I tried to warn you... Because the same forces are once again brewing… and what’s coming next will forever reshape everything you think you know about America. Start streaming it now at no cost here About Outlook Therapeutics Stock (NASDAQ:OTLK)Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Read More OTLK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OTLK Stock News HeadlinesMay 20 at 3:24 AM | americanbankingnews.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) to Post Q1 2025 Earnings of ($1.00) Per Share, HC Wainwright ForecastsMay 19 at 5:04 AM | americanbankingnews.comOutlook Therapeutics (NASDAQ:OTLK) Rating Reiterated by HC WainwrightMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Outlook Therapeutics on Strong EU Prospects and Solid Financial PositionMay 17, 2024 | msn.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Q2 2024 Earnings Call TranscriptMay 17, 2024 | finance.yahoo.comQ2 2024 Outlook Therapeutics Inc Earnings CallMay 15, 2024 | globenewswire.comOutlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateMay 14, 2024 | americanbankingnews.comOutlook Therapeutics (OTLK) Set to Announce Quarterly Earnings on ThursdayMay 13, 2024 | globenewswire.comOutlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDMay 9, 2024 | finance.yahoo.comOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastMay 9, 2024 | globenewswire.comOutlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastMay 3, 2024 | finance.yahoo.comGlobal $320 Billion Aviation Fuel Market Outlook, 2024-2029: Emission Reduction Initiatives, Rising Air Freight Demand, Emerging MarketsMay 3, 2024 | msn.comHow to fix Microsoft OutlookMay 2, 2024 | globenewswire.comOutlook Therapeutics® to Present at the Retina World Congress 2024April 29, 2024 | globenewswire.comOutlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseApril 29, 2024 | msn.comThese 5 programs are way better than Microsoft OutlookApril 29, 2024 | usnews.comHCLTech Falls Most in Nearly 17 Months on Lower-Than-Expected FY25 OutlookApril 29, 2024 | finance.yahoo.comBest's Market Segment Report: AM Best Maintains Stable Outlook on Insurance Markets of Gulf Cooperation CouncilApril 26, 2024 | finance.yahoo.comGlobal Aluminum Wire with a Focus on Aerospace Market Outlook 2023-2036April 26, 2024 | msn.comHow to Use Copilot in OutlookApril 22, 2024 | finance.yahoo.comBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to PositiveApril 22, 2024 | markets.businessinsider.comWGA Releases New Housing Finance OutlookApril 22, 2024 | msn.comOutlook: How to set up breaks between your meetingsApril 21, 2024 | finance.yahoo.comOutlook Therapeutics, Inc. (OTLK)April 18, 2024 | finance.yahoo.comWorld Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and PricesApril 18, 2024 | usnews.comBosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024See More Headlines Receive OTLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/22/2021Today5/21/2024Next Earnings (Estimated)8/12/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:OTLK CUSIPN/A CIK1649989 Webwww.outlooktherapeutics.com Phone(609) 619-3990FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Target$46.43 High Stock Price Target$100.00 Low Stock Price Target$20.00 Potential Upside/Downside+484.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($11.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,741.39% Return on Assets-167.29% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.11) per share Price / Book-7.16Miscellaneous Outstanding Shares13,010,000Free Float12,323,000Market Cap$103.43 million OptionableOptionable Beta0.28 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Ralph H. Thurman (Age 75)Independent Executive Chairman Comp: $207.5kMr. C. Russell Trenary III (Age 66)President, CEO & Director Comp: $610.9kMr. Lawrence A. Kenyon CPA (Age 58)Executive VP, CFO, Treasurer, Company Secretary & Director Mr. Jeffrey Evanson (Age 55)Chief Commercial Officer Comp: $451.17kMs. Alicia TozierSenior Vice President, Marketing & Market AccessMr. Joel PrieveSenior Vice President of Licensing and M&ADr. Surendra Sharma M.D.Senior Vice President of Medical AffairsDr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory AffairsMr. Jedd ComiskeySenior VP - Head of EuropeMore ExecutivesKey CompetitorsCurisNASDAQ:CRISPassage BioNASDAQ:PASGAlloVirNASDAQ:ALVRProtalix BioTherapeuticsNYSE:PLXAthira PharmaNASDAQ:ATHAView All CompetitorsInsiders & InstitutionsVirtu Financial LLCSold 49,933 shares on 5/20/2024Ownership: 0.140%American International Group Inc.Sold 74,302 shares on 5/14/2024Ownership: 0.030%Vanguard Group Inc.Sold 6,219,100 shares on 5/10/2024Ownership: 2.623%BNP Paribas Financial MarketsSold 81,876 shares on 5/1/2024Ownership: 0.035%Rosalind Advisors Inc.Bought 311,775 shares on 4/25/2024Ownership: 2.396%View All Insider TransactionsView All Institutional Transactions OTLK Stock Analysis - Frequently Asked Questions Should I buy or sell Outlook Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OTLK shares. View OTLK analyst ratings or view top-rated stocks. What is Outlook Therapeutics' stock price target for 2024? 8 Wall Street analysts have issued 12-month target prices for Outlook Therapeutics' shares. Their OTLK share price targets range from $20.00 to $100.00. On average, they predict the company's stock price to reach $46.43 in the next year. This suggests a possible upside of 508.5% from the stock's current price. View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts. How have OTLK shares performed in 2024? Outlook Therapeutics' stock was trading at $7.88 at the start of the year. Since then, OTLK stock has decreased by 3.2% and is now trading at $7.63. View the best growth stocks for 2024 here. When is Outlook Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our OTLK earnings forecast. How were Outlook Therapeutics' earnings last quarter? Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced its quarterly earnings data on Wednesday, December, 22nd. The company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.20) by $0.60. When did Outlook Therapeutics' stock split? Shares of Outlook Therapeutics reverse split on the morning of Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Outlook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX). Who are Outlook Therapeutics' major shareholders? Outlook Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.62%), Rosalind Advisors Inc. (2.40%), Virtu Financial LLC (0.14%), BNP Paribas Financial Markets (0.03%) and American International Group Inc. (0.03%). Insiders that own company stock include C Russell Trenary III, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Terry Dagnon and Yezan Munther Haddadin. View institutional ownership trends. How do I buy shares of Outlook Therapeutics? Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OTLK) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account Before It’s Too LateWeiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.